Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.450.1%
QQQ
717.500.2%
BTC/USD
79725.100.7643%
DIA
532.880.22%
GLD
406.530.06%
TLT
82.240.04%

Fulcrum Therapeutics Inc

FULCNASDAQ
Trade with Public
Trade with Public
$3.85
0.010.26%
At close: Sep 4, 5:00 PM EST
$3.85
N/A
After Hours: Sep 4, 4:00 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareStock Report

Fulcrum Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Fulcrum Therapeutics (FULC).

Price Target Range — 11 Quarters

Analyst Consensus — 11 Analysts

3Buy
5Hold
3Sell
Consensus RatingHold# Analysts11Avg. Consensus PT$8Upside to Avg. PT+107.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jun 3, 2026JP Morgan—DowngradeOverweight→Underweight—
Jun 2, 2026StifelJames CondulisDowngradeBuy→Hold$25→$3
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
JP Morgan Downgrades Fulcrum Therapeutics to Underweight

JP Morgan downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Overweight to Underweight.
Benzinga Newsdesk

This Truist Securities Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday

Analyst rating changes: Stifel and Piper Sandler downgrade FULC, while Truist, Jefferies downgrade TMHC and SARO respectively. See more views.
Avi Kapoor

PRO
Stifel Downgrades Fulcrum Therapeutics to Hold, Lowers Price Target to $3

Stifel analyst James Condulis downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Buy to Hold and lowers the price target from $25 to $3.
Benzinga Newsdesk

PRO
Piper Sandler Downgrades Fulcrum Therapeutics to Underweight, Lowers Price Target to $3

Piper Sandler analyst Edward Tenthoff downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Overweight to Underweight and lowers the price target from $23 to $3.
Benzinga Newsdesk

PRO
Truist Securities Downgrades Fulcrum Therapeutics to Hold, Lowers Price Target to $4

Truist Securities analyst Gregory Renza downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Buy to Hold and lowers the price target from $17 to $4.
Benzinga Newsdesk

PRO
Leerink Partners Downgrades Fulcrum Therapeutics to Market Perform, Lowers Price Target to $4

Leerink Partners analyst Joseph Schwartz downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Outperform to Market Perform and lowers the price target from $24 to $4.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved